SOBI — Swedish Orphan Biovitrum AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK165.02bn
- SEK180.18bn
- SEK28.24bn
Europe Research Roundup: Adidas, Berkeley Group, Saint-Gobain
Brief: SOBI Announces FDA Acceptance Of New Drug Application For Avatrombopag
Brief: David Meek Elected Chair Of Board Of SOBI
RBC names specialty pharma and biotech launches to watch in 2025
Europe Research Roundup: Babcock International, Scout24 SE, UPM-Kymmene Oyj
Brief: Swedish Orphan Biovitrum Says Nomination Committee Of Company Proposes David Meek As New Chair Of Board Of Directors
Brief: SOBI Says All Secondary Endpoints Favoured Pegcetacoplan Treatment
Brief: SOBI Updates 2024 Revenue Outlook
Brief: SOBI Q3 EBIT SEK 2,038 Million
Brief: SOBI, Enable Injections Announce Development and Distribution Agreement
Brief: SOBI, Apellis Announce Positive Topline Results From VALIANT Study
Top of the Street: Sika, Haleon, Anglo American, VAT Group
Jefferies cuts SOBI to 'hold' as competition weighs
Brief: Sobi Raises 2024 Revenue Growth Outlook
Brief: SOBI Q2 EBIT SEK 612 Million Vs. IBES Estimate SEK 549.9 Million
Earnings Poll: Swedish Orphan Biovitrum AB (publ) second quarter results due on July 16
Brief: SOBI Initiates Application To FDA For Sel-212
Brief: European Commission Grants SOBI Marketing Authorisation For Altuvoct For Treatment Of Haemophilia A
Brief: Sobi's Emapalumab-Lzsg Gets FDA Fast Track Status